M&T Bank
RVMD icon

M&T Bank’s Revolution Medicines RVMD Stock Holding History

M&T Bank’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
9,451
+894
+10% +$131K 0.01% 685
2026
Q1 		$831K Buy
8,557
+497
+6% +$50.2K ﹤0.01% 942
2025
Q4 		$642K Buy
+8,060
New +$528K ﹤0.01% 1018

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

M&T Bank's RVMD Position: Q2 2026 in Review

M&T Bank increased its Revolution Medicines (RVMD) stake by 10% in Q2 2026, buying an estimated $131K and bringing the position to 9,451 shares worth $1.77M. The position accounts for 0.01% of the portfolio, ranked #685.

M&T Bank first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • M&T Bank held 9,451 shares of Revolution Medicines worth $1.77M as of Q2 2026.
  • M&T Bank bought 894 Revolution Medicines shares in Q2 2026, an estimated $131K.
  • Revolution Medicines made up 0.01% of M&T Bank's portfolio in Q2 2026, its #685 holding.
  • M&T Bank first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.